红日药业：2025年前三季度净利润约8076万元

Company Performance - Hongri Pharmaceutical reported a revenue of approximately 4.149 billion yuan for the first three quarters of 2025, representing a year-on-year decrease of 6.59% [1] - The net profit attributable to shareholders of the listed company was approximately 80.76 million yuan, down 52.03% year-on-year [1] - Basic earnings per share were 0.03 yuan, reflecting a decrease of 50% compared to the previous year [1] Market Context - The market capitalization of Hongri Pharmaceutical is currently 11.4 billion yuan [1] - The A-share market has recently surpassed 4,000 points, indicating a significant market resurgence after a decade of stagnation, with a new "slow bull" market pattern emerging [1]